Abstract
Liver
metastasis
is
a
leading
cause
of
mortality
from
malignant
tumors
and
significantly
impairs
the
efficacy
therapeutic
interventions.
In
recent
years,
both
preclinical
clinical
research
have
made
significant
progress
in
understanding
molecular
mechanisms
strategies
liver
metastasis.
Metastatic
tumor
cells
different
primary
sites
undergo
highly
similar
biological
processes,
ultimately
achieving
ectopic
colonization
growth
liver.
this
review,
we
begin
by
introducing
inherent
metastatic‐friendly
features
We
then
explore
panorama
conclude
three
continuous,
yet
distinct
phases
based
on
liver's
response
to
This
includes
metastatic
sensing
stage,
stress
support
stage.
discuss
intricate
interactions
between
various
resident
recruited
cells.
addition,
emphasize
critical
role
spatial
remodeling
immune
Finally,
review
advancements
challenges
faced
management
Future
precise
antimetastatic
treatments
should
fully
consider
individual
heterogeneity
implement
targeted
interventions
stages
Diagnostics,
Год журнала:
2025,
Номер
15(5), С. 644 - 644
Опубликована: Март 6, 2025
Osteosarcoma
(OS)
is
the
most
common
primary
malignant
bone
tumor,
predominantly
affecting
children,
adolescents,
and
young
adults.
Epithelial-mesenchymal
transition
(EMT),
a
process
in
which
epithelial
cells
lose
their
cell-cell
adhesion
gain
migratory
invasive
properties,
has
been
extensively
studied
various
carcinomas.
However,
its
role
mesenchymal
tumors
like
osteosarcoma
remains
less
explored.
EMT
increasingly
recognized
as
key
factor
progression
of
osteosarcoma,
contributing
to
tumor
invasion,
metastasis,
resistance
chemotherapy.
This
narrative
review
aims
provide
comprehensive
overview
molecular
mechanisms
driving
highlighting
involvement
signaling
pathways
such
TGF-β,
transcription
factors
Snail,
Twist,
Zeb,
microRNAs
modulating
EMT.
Furthermore,
we
discuss
how
correlates
with
poor
prognosis
therapy
patients,
emphasizing
potential
targeting
for
therapeutic
intervention.
Recent
advancements
understanding
have
opened
new
avenues
treatment,
including
inhibitors
combination
therapies
aimed
at
overcoming
drug
resistance.
By
integrating
biological
insights
clinical
implications,
this
underscores
importance
critical
target.
